<code id='1366911F77'></code><style id='1366911F77'></style>
    • <acronym id='1366911F77'></acronym>
      <center id='1366911F77'><center id='1366911F77'><tfoot id='1366911F77'></tfoot></center><abbr id='1366911F77'><dir id='1366911F77'><tfoot id='1366911F77'></tfoot><noframes id='1366911F77'>

    • <optgroup id='1366911F77'><strike id='1366911F77'><sup id='1366911F77'></sup></strike><code id='1366911F77'></code></optgroup>
        1. <b id='1366911F77'><label id='1366911F77'><select id='1366911F77'><dt id='1366911F77'><span id='1366911F77'></span></dt></select></label></b><u id='1366911F77'></u>
          <i id='1366911F77'><strike id='1366911F77'><tt id='1366911F77'><pre id='1366911F77'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:comprehensive    Page View:48321

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In